Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07314333 · ClinicalTrials.gov registry record · Phase 1
A Trial to Assess How Centanafadine Interacts With Stimulants in the Body
A Phase 1 study of ADHD, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT07314333: Recruiting Phase 1 study of ADHD, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT07314333 is a Phase 1 study of ADHD that is actively recruiting participants, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 42 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07314333, a Phase 1 study of ADHD, is actively recruiting participants, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
Conditions Studied
Interventions
- DRUG Methylphenidate
- DRUG Centanafadine
- DRUG Lisdexamfetamine
Study Locations (1)
Utah
- ICON - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-02-05 |
| Est. Completion | 2026-04-03 |
| Phase | Phase 1 |
What NCT07314333 shows while recruiting
NCT07314333 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (78% lower).
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 3 interventions - of which Methylphenidate is the first listed.
NCT07314333 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT07314333 about?
NCT07314333 is a clinical study titled "A Trial to Assess How Centanafadine Interacts With Stimulants in the Body". This study will look at how centanafadine works when taken together with stimulant medicines in healthy adults, and whether combining them affects how the body responds.
What is the current status of trial NCT07314333?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-02-05. Estimated completion is 2026-04-03.
What conditions does trial NCT07314333 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT07314333?
The interventions under investigation include: Methylphenidate (DRUG), Centanafadine (DRUG), Lisdexamfetamine (DRUG).
Who is sponsoring clinical trial NCT07314333?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07314333 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07314333's enrollment target sits among peer trials
42 52nd of 75 higher than 23 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD
COMPLETED · Phase 1
-
TD-9855 Mass Balance Study
COMPLETED · Phase 1
-
Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)
COMPLETED · Phase 1
-
The Reinforcing Mechanisms of Smoking in Adult ADHD
COMPLETED · Phase 1
-
Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI)
RECRUITING · NA
-
Target ADHD Executive Working Memory Replication Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI